Cesar Simbaqueba Clavijo

Dr. Cesar Simbaqueba Clavijo


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CCCesar Simbaqueba Clavijo
Cesar Simbaqueba Clavijo
OOORHUE ODARO
ORHUE ODARO
AGAyush Gandhi
Ayush Gandhi
KKKwame Koom-Dadzie
Kwame Koom-Dadzie
AMArine Musaelyan
Arine Musaelyan
JMJoanna Grace Manzano
Joanna Grace Manzano
Background/Objectives: Few studies have focused on patients with immune-related adverse events (irAEs) after immune checkpoint inhibitor (ICI) treatment who were cared for primarily by hospitalists. The objective of our study was to describe the patterns and outcomes of adult solid-tumor cancer patients admitted to our onco-hospital medicine service. Methods: We retrospectively reviewed patients with solid tumors who received ICIs and were admitted to our service in 2021–2022 with an irAE and compared them to a control group (IOTOX vs. NO IOTOX, respectively). The primary outcome was the patterns of irAEs requiring hospitalization; secondary outcomes included 30-day emergency room visit, readmission, and 30-day mortality. Results: There were 144 patients in the IOTOX group and 286 controls. The most common tumor type was lung and thoracic malignancies (62, 43.1%). The most common ICI causing the irAEs was pembrolizumab (66, 45.8%). The most common irAEs were pneumonitis (49, 34%), colitis (28, 19.4%), hepatitis (18, 12.5%), and myocarditis (16, 11.1%). Of the 144 patients, eight (6%) died from the hospitalization irAE. Fifteen (15.6%) had an ER visit within 30 days due to the same irAE, and thirteen (13.7%) were readmitted. Survival at 30 days after discharge did not differ significantly between groups. Conclusions: Despite many patients having severe irAEs and irAEs associated with higher mortality, they generally had a favorable outcome compared to the literature.

31 October 2023 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
MMMayoora Muthu
Mayoora Muthu
SDShalini Dalal
Shalini Dalal
MGMarina George
Marina George
CCCesar Simbaqueba Clavijo
Cesar Simbaqueba Clavijo
CLCaitlin Lenz
Caitlin Lenz
NNNico Nortje
Nico Nortje

1 December 2023 in Annals of Internal Medicine: Clinical Cases
Verified
Journal Article
Closed access
CCCesar Simbaqueba Clavijo
Cesar Simbaqueba Clavijo
Ashley AaroeAshley Aaroe
Ashley Aaroe
DRDavid Rubio
David Rubio
MLMonica Loghin
Monica Loghin
JTJeffrey Treiber
Jeffrey Treiber
MSMaria Suarez-Almazor
Maria Suarez-Almazor

19 May 2022 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
PDF file
KHKevin A. Honan
Kevin A. Honan
DMDominique Monlezun
Dominique Monlezun
ABAndrew Badalamenti
Andrew Badalamenti
JKJin wan Kim
Jin wan Kim
VLVictor Liu
Victor Liu
CICezar Iliescu
Cezar Iliescu
This is the largest longitudinal nationally representative study of mortality, cost, and valvular procedure (pulmonary and tricuspid valve repair/replacements [PVR and TVR]) by malignant carcinoid tumor (MCT).

19 May 2022 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
PDF file
JKJin wan Kim
Jin wan Kim
DMDominique Monlezun
Dominique Monlezun
KHKevin A. Honan
Kevin A. Honan
CCCesar Simbaqueba Clavijo
Cesar Simbaqueba Clavijo
SCSiddharth Chauhan
Siddharth Chauhan
CICezar Iliescu
Cezar Iliescu
We performed the largest multi-year nationwide study of mortality, cost, and procedural volume of transcatheter aortic valve replacement (TAVR) for patients with and without active cancer.

5 April 2024 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
CCCesar Simbaqueba Clavijo
Cesar Simbaqueba Clavijo
MAMehmet Altan
Mehmet Altan
MFMaria Franco-Vega
Maria Franco-Vega
MRMelvin Rivera
Melvin Rivera
APAnisha Patel
Anisha Patel
"CLO24-066: Cemiplimab Use in Advanced Cutaneous Squamous Cell Carcinoma and Non–Small Cell Lung Cancer: Risk Factors Associated With Mortality" published on 05 Apr 2024 by National Comprehensive Cancer Network.